The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Headline
Nearly 70 organizations, including the AHA, today urged congressional leaders to advance the House-passed Pandemic and All-Hazards Preparedness…
Headline
About 80 percent of new HIV infections in the U.S. in 2016 were transmitted from the nearly 40 percent of people with HIV who either did not know they had HIV…
Headline
Historic flooding in parts of the Midwest caused a number of Nebraska hospitals to be inaccessible by ground transportation, the Nebraska Hospital Association…
Headline
The Senate Appropriations Committee’s Subcommittee on Labor, Health and Human Services, Education and Related Agencies today held a
Insights and Analysis
In this AHA Stat Blog, Institute for Diversity and Health Equity President and CEO Duane Reynolds shares some takeaways from the recent ACHE conference and…
Insights and Analysis
This week, as part of the South by Southwest (SXSW) festival’s Interactive Health and MedTech track, the American Hospital Association and hospital leaders…